neuro-central.com
Depatux-M fails to meet primary endpoint in late-stage trial for newly diagnosed glioblastoma - Neuro Central
Enrollment in all ongoing Depatux-M studies has been halted for newly diagnosed glioblastoma due to lack of survival benefit.